📰 Apic Bio News
Apic Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Apic Bio. Real-time updates on events, politics, business and more.
May 22, 2024
The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is projected to reach USD 2,517 million by 2032, up from USD 1,413 million in 2022, growing at a CAGR of 6.1% during the forecast period from 2022 to 2032. This growth is driven by several key factors, including increasing awareness of AATD...
November 7, 2023
~ Announced FDA clearance of Investigational New Drug application for AMT-260 in refractory mesial temporal lobe epilepsy ~ ~ On track to provide clinical update from U.S. and European Phase I/II...
August 1, 2023
~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and clinical benefits...
May 9, 2023
~ Clinical update from U.S. Phase I/II trial in Huntington's disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in refractory
February 21, 2023
The prevalence of amyotrophic lateral sclerosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of amyotrophic lateral
February 21, 2023
/PRNewswire/ -- DelveInsights Amyotrophic Lateral Sclerosis Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed,...
January 31, 2023
~ License of APB-102 further strengthens uniQure's pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure's c9orf72-ALS
January 31, 2023
31.01.2023 - ~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS program have the potential to address most ... Seite 1